Mitragynine and Its Diastereomers: Why Accurate Mass Is Not Enough

High-resolution mass spectrometry can provide excellent mass accuracy while leaving an important identity problem unresolved. Compounds with the same molecular formula may require chromatographic separation before a laboratory can report them individually.

Kratom alkaloids provide a concrete example. A result labeled “mitragynine” may need examination of the chromatographic method rather than simple acceptance of an accurate precursor mass and matching fragments.

What the urine study demonstrated

Helander and Rylski examined 29 consecutive urine specimens positive by a routine LC–HRMS method using a 100 µg/L cutoff. An improved method separated mitragynine, speciogynine, speciociliatine, and mitraciliatine. All 29 contained mitragynine, but eight had mitragynine itself below the routine cutoff, at 11–78 µg/L. Co-eluting alkaloids had contributed to the original result. The improved method reported a 1 µg/L quantification limit for each diastereomer. Peer-reviewed study, online November 4, 2022; full-text methods and results consulted, DOI: 10.1002/dta.3391.

The study did not show that those eight specimens contained no mitragynine. It showed why the concentration attributed to a named analyte, and the resulting threshold classification, depend on separation.

Identity criteria must address the actual alternatives

When several compounds share the relevant exact mass and fragments, adding more confidence in those same shared features may not resolve identity. Review retention behavior against appropriate reference materials and the method's demonstrated separation under actual operating conditions.

Ask whether selectivity experiments included the relevant alkaloids together, not only each one in isolation. Examine mixtures with unequal proportions when that reflects the intended specimens. A separation that looks satisfactory in a balanced reference mixture may require closer assessment when a minor analyte sits beside a much larger neighboring peak.

The question is specific to the method. The published finding should not be generalized into an assertion that all mitragynine LC–MS results are unreliable. A laboratory with appropriate separation and validation may have already addressed the problem.

A cutoff is not a pharmacological threshold

Even when the analytical measurement is correct, a reporting cutoff serves the purpose assigned by the testing program. It is not automatically a threshold for impairment, toxicity, or a particular product source.

For case review, distinguish an incorrect compound assignment, an inaccurate concentration assignment, and a policy-based classification above or below a cutoff. Those issues can lead to different corrective actions. The original data may support a more limited finding even if the original numerical interpretation needs revision.

Check the units as well. One microgram per liter equals one nanogram per milliliter. That equivalence does not authorize comparison of urine values with blood values or with a cutoff established for another matrix.

What to request from the laboratory

Useful records include the relevant method revision, chromatograms of reference materials and authentic specimens, integration rules, selectivity experiments, and criteria for identifying each alkaloid. Ask whether the reported concentration represents one resolved peak or a combined response.

If reanalysis is proposed, document the retained specimen's condition and the purpose of the new examination. The question may be whether mitragynine is present, whether its concentration exceeds a specified cutoff, or how several alkaloids contributed to an earlier signal. State the question before choosing the analysis.

The broader lesson is that instrument sophistication does not remove the need to define the measurand. See analytical selectivity and chromatography for the underlying concepts.